The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers


Background: Compound Salvia Pellet (T89), consisting of Danshen (salvia miltiorrhiza), Sanqi (panax notoginseng), and Borneol (Cinnamomum camphora), has been used worldwide for 14 years for chronic angina treatment. Purpose: A dose escalation study to determine the maximum tolerance dose (MTD) in Chinese population to support a proposed dose regimen change. Methods: Forty-six participants (age 18 to 45 yrs, male to female ratio = 1:1) were divided into a series of 6 patients cohorts, and sequentially assigned into one of the escalating dose groups, starting from 540 mg, the clinical doses, until 4 out of 6 subjects experience clinical Adverse Events (AEs) or when the pre-defined 3510 mg dose level is reached and completed. All doses were given orally as a single dose 2 hours after breakfast. Adverse events, vital signs, 12-lead ECG, clinical and laboratory parameters and medical evaluation were conducted as outcome measures. Results: Study completed at the highest pre-defined dose level of 3510 mg dose as never had 4/6 of subject experience AEs in any dose levels studied. All participants completed the study and data were included in the safety analysis. The only moderate AE observation (muscle damage) was observed at 2970 mg dose and was recovered without any medical treatment, and all other AEs (ECG, dizziness, muscle damage) were mild and may (5 cases) or may not (9 cases) be related to testing drug and were all self-resolved within 30 min after dose. Conclusion: Given as single oral dose, Compound Salvia Pellet is safe and well-tolerated up to the 3510 mg studied. The MTD value of Compound Salvia Pellet is unknown from this trial and must be higher than 3510 mg, 13 times higher than its current clinical dose.

Share and Cite:

Y. Zhou, Y. Cui, X. Zhao, Y. Huo, Z. Nie, M. Zhao, Z. Guo and H. Sun, "The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers," Pharmacology & Pharmacy, Vol. 4 No. 6, 2013, pp. 490-495. doi: 10.4236/pp.2013.46071.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] C.-E. Deng, “Progress on Pharmacological and Clinical Application of Salvia Miltiorrhiza,” Lishizhen Medicine and Materia Medica Research, Vol. 14, No. 12, 2003, p. 776.
[2] N. Ding, “Research Advancement and Clinical Application of Compound Danshen,” Chinese Traditional and Herbal Drugs, Vol. 33, No. 12, 2002, pp. 1147-1148. (in Chinese)
[3] Z. X. Guo, W. Jia, W. Y. Gao, et al., “Clinical Investigation of Composite Danshen Pill for the Treatment of Angina Pectoris,” Chinese Journal of Natural Medicines, Vol. 1, No. 2, 2003, pp. 124-128. (in Chinese)
[4] Y. H. Shi, “Comparative Study of Composite Danshen Droplet Pills and Sordid in Treatment of Patients with Chronic Stable Angina,” Zhongguo Zhong Xi Yi Jie He Za Zhi, Vol. 17, No. 1, 1997, pp. 23-25. (in Chinese)
[5] W. Zhou and T. J. Ruigrok, “Protective Effect of Danshen during Myocardial Ischemia and Reperfusion: An Isolated Rat Heart Study,” The American Journal of Chinese Medicine, Vol. 18, No. 1, 1990, pp. 19-24. doi:10.1142/S0192415X90000046
[6] A. M. Wang, S. H. Sha, W. Lesniak, et al., “Tanshinone (Salviae miltiorrhizae Extract) Preparations Attenuate Aminoglycoside-Induced Free Radical Formation: In Vitro and Ototoxicity in Vivo,” Antimicrobial Agents and Chemotherapy, Vol. 47, No. 6, 2003, pp. 1836-1841. doi:10.1128/AAC.47.6.1836-1841.2003
[7] J. Wang, J. Xu, J. B. Zhong, et al., “Effect of Radix Notoginseng Saponins on Platelet Activating Molecule Expression and Aggregation in Patients with Blood Hyperviscosity Syndrome,” Zhongguo Zhong Xi Yi Jie He Za Zhi, Vol. 24, No. 4, 2004, pp. 312-316. (in Chinese)
[8] P. Chan, G. N. Thomas and B. Tomlinson, “Protective Effects of Trilinolein Extracted from Panax Notoginseng against Cardiovascular Disease,” Acta Pharmacologica Sinica, Vol. 23, No. 12, 2002, pp. 1157-1162.
[9] W. Zhou, H. Chai, P. H. Lin, et al., “Molecular Mechanisms and Clinical Applications of Ginseng Root for Cardiovascular Disease,” Medical Science Monitor, Vol. 10, No. 8, 2004, pp. RA187-RA192.
[10] Y.-J. Wu, C.-Y. Hong, S.-J. Lin, P. Wu and M.-S. Shiao, “Increase of Vitamin E Content in LDL and Reduction of Atherosclerosis in Cholesterol-Fed Rabbits by a WaterSoluble Antioxidant-Rich Fraction of Salvia miltiorrhiza,” Thrombosis, and Vascular Biology, Vol. 18, 1998, pp. 481-486. doi:10.1161/01.ATV.18.3.481
[11] O. Karmin, E. G. Lynn, R. Vazhappilly, K. K. W. AuYeung, D.-Y. Zhu and Y. L. Siow, “Magnesium Tanshinoate B (MTB) Inhibits Low Density Lipoprotein Oxidation,” Life Sciences, Vol. 68, No. 8, 2001, pp. 903-912. doi:10.1016/S0024-3205(00)00989-9
[12] T. Kyoko, O. Xinshou, K. Katsuko, N. Norio, H. Masao and B. Akemichi, “Sodium Tanshinone IIA Sulfonate Derived from Danshen (Salvia miltiorrhiza) Attenuates Hypertrophy Induced by Angiotensin II in Cultured Neonatal Rat Cardiac Cells,” Biochemical Pharmacology, Vol. 64, No. 4, 2002, pp. 745-750. doi:10.1016/S0006-2952(02)01250-9
[13] G. Wang, L. Wang, Z. Y. Xiong, B. Mao and T. Q. Li, “Compound Salvia Pellet, a Traditional Chinese Medicine, for the Treatment of Chronic Stable Angina Pectoris Compared with Nitrates: A Meta-Analysis,” Medical Science Monitor, Vol. 12, No. 1, 2006, pp. SR1-SR7.
[14] P. Mickie, R. Peled, L. Matityhau, et al., “Reasons for Overprescription of Mononitrates: The Paradigm of Stable Angina Pectoris Treatment,” Current Therapeutic Research, Vol. 64, No. 9, 2003, pp. 662-675. doi:10.1016/j.curtheres.2003.09.013
[15] S. P. Glasser, “Clinical Mechanisms of Nitrate Action,” American Journal of Cardiology, Vol. 81, No. 1, 1998, pp. 49A-53A. doi:10.1016/S0002-9149(97)00998-3
[16] S. D. Fihn, S. V. Williams, J. Daley, et al., “American College of Cardiology, American Heart Association, American College of Physicians-American Society of Internal Medicine Guidelines for the Management of Patients with Chronic Stable Angina: Treatment,” Annals of Internal Medicine, Vol. 135, No. 8, 2001, pp. 616-632. doi:10.7326/0003-4819-135-8_Part_1-200110160-00014
[17] M. Eccles, “North of England Stable Angina Guideline Development Group: North of England Evidence Based Guidelines Development Project: Summary Version of Evidence Based Guideline for the Primary Care Management of Angina,” BMJ, Vol. 312, 1996, pp. 827-832. doi:10.1136/bmj.312.7034.827
[18] R. J. Gibbons, J. Abrams, K. Chatterjee, et al., “ACC/ AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina—Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina),” Circulation, Vol. 107, 2003, pp. 149-158. doi:10.1161/01.CIR.0000047041.66447.29
[19] S. Silber, “Nitrates: Why and How Should They Be Used Today?” European Journal of Clinical Pharmacology, Vol. 3, No. 1, 1990, pp. S35-S51. doi:10.1007/BF01417564
[20] P. A. Todd, K. L. Goa and H. D. Langtry, “Transdermal Nitroglycerin (Glyceryl Trinitrate): A Review of Its Pharmacology and Therapeutic Use,” Drugs, Vol. 40, No. 6, 1990, pp. 880-902. doi:10.2165/00003495-199040060-00009
[21] S. Y. Zai, R. Chen and X. H. Wu, “Clinical Observation on Compound Salvia Pellet in the Treatment of 41 Cases’ Migraine,” Journal of Practical, Traditional Chinese Medicine, Vol. 22, No. 1, 2006, p. 26.
[22] G. Y. Hu and F. H. Cai, “Clinical Observation of Curative Effect of Compound Danshen Pellet in Unstable Angina,” Chinese Journal of Cardiovascular Review, Vol. 1, No. 1, 2003, pp. 38-40.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.